Misaki Sekiguchi

Metabolic resistance of Abeta3pE-42, epitope of the anti-Alzheimer therapeutic antibody, donanemab.

This paper investigates the metabolic stability and deposition of A{beta}3pE-42, a target of the Alzheimer's antibody donanemab, showing it is more stable than other A{beta}X-42 species and accumulates with age.

Neprilysin-sensitive amyloidogenic Aβ versus IDE-sensitive soluble Aβ: a probable mechanistic cause for sporadic Alzheimer's disease

This study compares the roles of NEP and IDE in Aβ metabolism using double knockout mice, finding NEP primarily degrades insoluble Aβ and its deficiency contributes to AD pathology.

An isogenic panel of single App knock-in mouse models of Alzheimer's disease confers differential profiles of β-secretase inhibition and endosomal abnormalities

This study develops App knock-in mice without Swedish mutations to investigate β-secretase inhibition and endosomal abnormalities in Alzheimer's disease.

New App knock-in mice that accumulate wild-type human Aβ as rapidly as AppNL-G-F mice exhibit intensive cored plaque pathology and neuroinflammation.

This paper introduces a new mouse model that accumulates wild-type human Aβ rapidly, showing more severe cored plaque pathology and neuroinflammation than existing models.

Somatostatin receptor subtypes 1 and 4 redundantly regulate neprilysin, the major amyloid beta-degrading enzyme, in brain

This study identifies SST1 and SST4 as redundant regulators of neprilysin, a key amyloid beta-degrading enzyme, and shows that targeting these receptors reduces Aβ pathology and improves cognition in an AD mouse model.